중증근무력증(MG) : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Myasthenia Gravis (MG) Emerging Therapy and TPP Insights

Thelansis's "Myasthenia Gravis (MG) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Myasthenia Gravis (MG) Overview

Myasthenia gravis is an autoimmune disorder in which the immune system produces antibodies that disrupt communication between nerves and muscles, causing fluctuating weakness that can affect the eyes, face, throat, limbs, and, in severe cases, breathing. For decades, treatment relied heavily on broad immune suppression through corticosteroids and related agents, which controlled symptoms but carried substantial long-term side effects. That has changed with two new classes of precision therapy targeting the specific immune mechanisms driving the disease rather than suppressing the immune system broadly, one blocking a receptor responsible for recycling harmful antibodies and the other interrupting a separate pathway that damages the nerve-muscle junction directly. Several agents within each class are now approved, giving physicians the ability to switch options when one is not well tolerated, and some therapies specifically address a less common antibody subtype that previously had fewer treatment options. These newer therapies are generally used alongside, rather than replacing, established immune-modulating treatment, with research now expanding toward B-cell targeted approaches.

Key Highlights

• In Germany, diagnosed Myasthenia Gravis cases are projected to increase from 7,567 in 2025 to 8,099 by 2035.
• Myasthenia Gravis is a rare autoimmune neuromuscular disorder causing fluctuating muscle weakness and fatigue.
• Despite available therapies, many patients continue to experience inadequate disease control and frequent exacerbations.
• Significant unmet need remains for targeted therapies that provide sustained symptom control and improved quality of life.

Market Overview

• The Germany Myasthenia Gravis market is projected to grow from $95M in 2025 to $200M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologics and complement inhibitors
• Expanding development of novel immunotherapies
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• ImmunAbs Inc.
• NMD Pharma A/S
• Kyverna Therapeutics
• Amgen
• Janssen Research & Development, LLC
• UCB Biopharma SRL
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Harbour BioMed (Guangzhou) Co. Ltd.
• Argenx
• COUR Pharmaceutical Development Company, Inc.
• RemeGen Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Dianthus Therapeutics
• Cartesian Therapeutics
• Ra Pharmaceuticals, Inc.
• Clinique Neuro-Outaouais
• Kite, A Gilead Company
• Arcellx, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)